Molecular Docking NS4B of DENV 1-4 with Known Bioactive Phyto-chemicals

Overview

Journal Bioinformation

Specialty Biology

Date 2017 Feb 3

PMID 28149049

Citations 4

Authors

Anubrata Paul

Arpana Vibhuti

Samuel Raj

Affiliations

Soon will be listed here.

Abstract

Dengue disease is a global disease that has no effective treatment. The dengue virus (DENV) NS4B is a target for designing specific antivirals due to its importance in viral replication. Medicinal plants have been a savior for dengue virus as they consist of a class of phytochemicals having anti-viral activity and can pose a new approach ofstrong drug against viruses. The present study analyzes the activity of compounds against NS4B of DENV (1-4) serotypes. In this study Catechin, Cianidanol, Epicatechin, Eupatoretin, Glabranin, Laurifolin, DL-Catechin, astherapeutic agents were filtered by using Lipinski rule's five and the drug-likeness property of these agents were used for assessment of pharmacological properties. The molecular docking results presented the 2-D structures of bioactive complex, which interacted with especially conserved residues of target domains. Interestingly, we find the Catechin, Laurifolin, Cianidanol have highest binding energy against NS4B in DENV-1,2,4 which is evident by the formation of more hydrogen bonds with the amino acid residues at the binding site of the receptor. Our results revealed that the bioactive compound, especially Catechin has significant anti-dengue activities. In addition, this study may be helpful in further experimental investigations.

Citing Articles

Antiviral Activity of Catechin against Dengue Virus Infection.

Yi B, Chew B, Chen H, Lee R, Fong Y, Chin W Viruses. 2023; 15(6).

PMID: 37376676 PMC: 10305075. DOI: 10.3390/v15061377.

In vitro and in silico anti-dengue activity of compounds obtained from Psidium guajava through bioprospecting.

Trujillo-Correa A, Quintero-Gil D, Diaz-Castillo F, Quinones W, Robledo S, Martinez-Gutierrez M BMC Complement Altern Med. 2019; 19(1):298.

PMID: 31694638 PMC: 6836419. DOI: 10.1186/s12906-019-2695-1.

Molecular docking and ADME properties of bioactive molecules against human acid-beta-glucosidase enzyme, cause of Gaucher's disease.

Subramaniyan V, Mathiyalagan S, Praveenkumar A, Srinivasan P, Palani M, Ravichandran V In Silico Pharmacol. 2019; 6(1):3.

PMID: 30607316 PMC: 6314663. DOI: 10.1007/s40203-018-0039-3.

In silico targeting of non-structural 4B protein from dengue virus 4 with spiropyrazolopyridone: study of molecular dynamics simulation, ADMET and virtual screening.

Hussain W, Qaddir I, Mahmood S, Rasool N Virusdisease. 2018; 29(2):147-156.

PMID: 29911147 PMC: 6003060. DOI: 10.1007/s13337-018-0446-4.

References

Allonso D, Andrade I, Conde J, Coelho D, Rocha D, Silva M . Dengue Virus NS1 Protein Modulates Cellular Energy Metabolism by Increasing Glyceraldehyde-3-Phosphate Dehydrogenase Activity. J Virol. 2015; 89(23):11871-83. PMC: 4645330. DOI: 10.1128/JVI.01342-15. View

Bastos Lima A, Behnam M, El Sherif Y, Nitsche C, Vechi S, Klein C . Dual inhibitors of the dengue and West Nile virus NS2B-NS3 proteases: Synthesis, biological evaluation and docking studies of novel peptide-hybrids. Bioorg Med Chem. 2015; 23(17):5748-55. DOI: 10.1016/j.bmc.2015.07.012. View

Qamar T, Mumtaz A, Ashfaq U, Azhar S, Fatima T, Hassan M . Computer Aided Screening of Phytochemicals from Garcinia against the Dengue NS2B/NS3 Protease. Bioinformation. 2014; 10(3):115-8. PMC: 3974236. DOI: 10.6026/97320630010115. View

Aslam B, Ahmad J, Ali A, Paracha R, Tareen S, Khusro S . Structural modeling and analysis of dengue-mediated inhibition of interferon signaling pathway. Genet Mol Res. 2015; 14(2):4215-37. DOI: 10.4238/2015.April.28.4. View

Lei Y, Yu H, Dong Y, Yang J, Ye W, Wang Y . Characterization of N-Glycan Structures on the Surface of Mature Dengue 2 Virus Derived from Insect Cells. PLoS One. 2015; 10(7):e0132122. PMC: 4514477. DOI: 10.1371/journal.pone.0132122. View

Jadav S, Kaptein S, Timiri A, De Burghgraeve T, Badavath V, Ganesan R . Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus E protein inhibitors. Bioorg Med Chem Lett. 2015; 25(8):1747-1752. DOI: 10.1016/j.bmcl.2015.02.059. View

Kampmann T, Yennamalli R, Campbell P, Stoermer M, Fairlie D, Kobe B . In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses. Antiviral Res. 2009; 84(3):234-41. DOI: 10.1016/j.antiviral.2009.09.007. View

Vernekar S, Qiu L, Zhang J, Kankanala J, Li H, Geraghty R . 5'-Silylated 3'-1,2,3-triazolyl Thymidine Analogues as Inhibitors of West Nile Virus and Dengue Virus. J Med Chem. 2015; 58(9):4016-28. PMC: 4465584. DOI: 10.1021/acs.jmedchem.5b00327. View

Zhou G, Weng Z, Shao X, Liu F, Nie X, Liu J . Discovery and SAR studies of methionine-proline anilides as dengue virus NS2B-NS3 protease inhibitors. Bioorg Med Chem Lett. 2013; 23(24):6549-54. DOI: 10.1016/j.bmcl.2013.10.071. View

10.

Saokaew N, Poungpair O, Panya A, Tarasuk M, Sawasdee N, Limjindaporn T . Human monoclonal single-chain antibodies specific to dengue virus envelope protein. Lett Appl Microbiol. 2013; 58(3):270-7. DOI: 10.1111/lam.12186. View

11.

Austin S, Dowd K, Shrestha B, Nelson C, Edeling M, Johnson S . Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog. 2012; 8(10):e1002930. PMC: 3464233. DOI: 10.1371/journal.ppat.1002930. View

12.

Mary J, Paramasivan R, Shenbagarathai R . Identification of sequence motifs involved in Dengue virus-host interactions. J Biomol Struct Dyn. 2015; 34(3):676-87. DOI: 10.1080/07391102.2015.1042914. View

13.

Shah M, Wadood A, Rahman Z, Husnain T . Interaction and inhibition of dengue envelope glycoprotein with mammalian receptor DC-sign, an in-silico approach. PLoS One. 2013; 8(3):e59211. PMC: 3601059. DOI: 10.1371/journal.pone.0059211. View

14.

Panya A, Bangphoomi K, Choowongkomon K, Yenchitsomanus P . Peptide inhibitors against dengue virus infection. Chem Biol Drug Des. 2014; 84(2):148-57. DOI: 10.1111/cbdd.12309. View

15.

Cabarcas-Montalvo M, Maldonado-Rojas W, Montes-Grajales D, Bertel-Sevilla A, Wagner-Dobler I, Sztajer H . Discovery of antiviral molecules for dengue: In silico search and biological evaluation. Eur J Med Chem. 2016; 110:87-97. DOI: 10.1016/j.ejmech.2015.12.030. View

16.

Knehans T, Schuller A, Doan D, Nacro K, Hill J, Guntert P . Structure-guided fragment-based in silico drug design of dengue protease inhibitors. J Comput Aided Mol Des. 2011; 25(3):263-74. DOI: 10.1007/s10822-011-9418-0. View

17.

Lin M, Hsu H, Bartenschlager R, Fischer W . Membrane undulation induced by NS4A of Dengue virus: a molecular dynamics simulation study. J Biomol Struct Dyn. 2013; 32(10):1552-62. DOI: 10.1080/07391102.2013.826599. View

18.

Ichiyama K, Gopala Reddy S, Zhang L, Chin W, Muschin T, Heinig L . Sulfated polysaccharide, curdlan sulfate, efficiently prevents entry/fusion and restricts antibody-dependent enhancement of dengue virus infection in vitro: a possible candidate for clinical application. PLoS Negl Trop Dis. 2013; 7(4):e2188. PMC: 3636050. DOI: 10.1371/journal.pntd.0002188. View

19.

Malet H, Egloff M, Selisko B, Butcher R, Wright P, Roberts M . Crystal structure of the RNA polymerase domain of the West Nile virus non-structural protein 5. J Biol Chem. 2007; 282(14):10678-89. DOI: 10.1074/jbc.M607273200. View

20.

Velmurugan D, Mythily U, Rao K . Design and docking studies of peptide inhibitors as potential antiviral drugs for dengue virus ns2b/ns3 protease. Protein Pept Lett. 2013; 21(8):815-27. DOI: 10.2174/09298665113209990062. View